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Summary
Background—Supplementation of vitamin A in children aged 6–59 months improves child 
survival and is implemented as global policy. Studies of the efficacy of supplementation of infants 
in the neonatal period have inconsistent results. We aimed to assess the efficacy of oral 
supplementation with vitamin A given to infants in the first 3 days of life to reduce mortality 
between supplementation and 180 days (6 months).
Methods—We did an individually randomised, double-blind, placebo-controlled trial of infants 
born in the Morogoro and Dar es Salaam regions of Tanzania. Women were identified during 
antenatal clinic visits or in the labour wards of public health facilities in Dar es Salaam. In 
Kilombero, Ulanga, and Kilosa districts, women were seen at home as part of the health and 
demographic surveillance system. Newborn infants were eligible for randomisation if they were 
able to feed orally and if the family intended to stay in the study area for at least 6 months. We 
randomly assigned infants to receive one dose of 50 000 IU of vitamin A or placebo in the first 3 
days after birth. Infants were randomly assigned in blocks of 20, and investigators, participants’ 
families, and data analysis teams were masked to treatment assignment. We assessed infants on 
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day 1 and day 3 after dosing, as well as at 1, 3, 6, and 12 months after birth. The primary endpoint 
was mortality at 6 months, assessed by field interviews. The primary analysis included only 
children who were not lost to follow-up. This trial is registered with the Australian New Zealand 
Clinical Trials Registry (ANZCTR), number ACTRN12610000636055.
Findings—Between Aug 26, 2010, and March 3, 2013, 31 999 newborn babies were randomly 
assigned to receive vitamin A (n=15 995) or placebo (n=16 004; 15 428 and 15 464 included in 
analysis of mortality at 6 months, respectively). We did not find any evidence for a beneficial 
effect of vitamin A supplementation on mortality in infants at 6 months (26 deaths per 1000 
livebirths in vitamin A vs 24 deaths per 1000 livebirths in placebo group; risk ratio 1·10, 95% CI 
0·95–1·26; p=0·193). There was no evidence of a differential effect for vitamin A supplementation 
on mortality by sex; risk ratio for mortality at 6 months for boys was 1·08 (0·90–1·29) and for girls 
was 1·12 (0·91–1·39). There was also no evidence of adverse effects of supplementation within 3 
days of dosing.
Interpretation—Neonatal vitamin A supplementation did not result in any immediate adverse 
events, but had no beneficial effect on survival in infants in Tanzania. These results strengthen the 
evidence against a global policy recommendation for neonatal vitamin A supplementation.
Introduction
Every year, an estimated 6·9 million children die before their fifth birthday. About 44% of 
deaths of children younger than 5 years occur in the neonatal period, mostly in southeast 
Asia and sub-Saharan Africa.1 The Millennium Development Goal for child survival will 
not be achieved without additional investments to address newborn baby deaths. Interest to 
estimate trends and causes of newborn deaths2 and to reduce mortality with safe and 
efficacious interventions3 has increased. Vitamin A deficiency is thought to be a major 
public health issue in low-income countries.4,5 Evidence from a systematic review6 and 
meta-analyses7,8 of randomised controlled trials indicate a significant benefit of periodic 
vitamin A supplementation for children aged 6–59 months, reducing all-cause mortality by 
23–30%. This body of evidence prompted policy recommendations by WHO9 and catalysed 
the implementation of large-scale supplementation programmes for children younger than 5 
years to improve child survival.9
Results from studies to establish whether vitamin A supplementation can provide similar 
benefits in children younger than 6 months have conflicting results, ranging from no 
benefit10 to potential benefit11–13 or possible harm, at least in subsets of children.14,15 This 
conflicting evidence prompted the development of large trials to generate the necessary 
evidence to inform global programmes that aim to improve child survival.16
We did a trial in Tanzania to establish the effect on infant mortality of vitamin A 
supplementation given on the day of birth or within the next 2 days. This is one of three 
large trials recommended by a technical consultation team convened by WHO in December, 
2008, to inform global policy for or against newborn vitamin A supplementation. Two 
companion studies done in India and Ghana are reported elsewhere.17,18
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Methods
Study design and participants
We did a randomised double-blind, placebo-controlled trial in Dar es Salaam and Morogoro 
regions of Tanzania. The characteristics of the study areas have been described elsewhere.16 
In Dar es Salaam, we enrolled mothers and newborn babies from ten large antenatal clinics 
and labour wards in the catchment areas, and in the Morogoro region, the study was nested 
within the Ifakara Health Institute’s health and demographic surveillance system (HDSS). 
The Ifakara HDSS covers about 2400 km2 and is operational in 12 villages in Ulanga and 46 
in Kilombero. For the purpose of this study, we extended the surveillance area to include 13 
additional villages from an adjacent district of Kilosa. Ifakara HDSS is a member of the 
INDEPTH Network.19
In Dar es Salaam, we identified pregnant women either during regular antenatal visits or in 
the labour wards of public health facilities that had delivery services. In Kilombero, Ulanga, 
and Kilosa districts, pregnant women were seen at home during regular household visits as 
part of the HDSS rounds and in labour wards. All births that occurred as part of the HDSS or 
at designated labour wards were eligible for screening. Newborn babies of women who were 
part of HDSS were reported to dosing supervisors through self-reports, by field interviewers 
or village-based key informants. Key informants were remunerated for reporting births with 
a tiered incentive package that encouraged early reporting of births. At least one parent of 
every livebirth was asked for consent to participate in the study. Those who gave written 
informed consent were screened to establish whether the infant met the eligibility criteria. 
Newborn babies were eligible for randomisation if they were able to feed orally, if the 
family intended to stay in the study area for at least 6 months, and if parents provided 
written informed consent to participate. Babies who were enrolled in other trials were 
excluded.
We sought written individual consent to follow women’s pregnancy until delivery. For 
women who are unable to read and write, a witness was invited to observe and a health 
worker read the consent and asked the mother to thumb seal upon agreement. Information 
about household demographics, nutritional status, and pregnancy complications was 
collected from all mothers. An international data and safety monitoring board reviewed data 
quarterly and convened twice during the course of the study to complete interim analyses to 
decide whether to continue the trial on the basis of stopping rules decided a priori.20 The 
study protocol was approved by the Institutional Review Boards of the Harvard School of 
Public Health, Ifakara Health Institute, Medical Research Coordinating Council of Tanzania, 
and by the WHO Ethical Review Committee.
Randomisation and masking
We randomly assigned infants to receive either vitamin A or a placebo. The unit of 
randomisation was the individual infant. Block randomisation was done at WHO (Geneva, 
Switzerland) in block sizes of 20 (ten infants received vitamin A and ten received placebo). 
Codes for the experimental regimens were kept with the data and safety monitoring board 
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and broken during the analysis after a cleaned and locked database for the study was 
submitted to WHO.
Strides Arcolab (Bangalore, India) supplied the capsules for this study and the companion 
studies in India and Ghana. Each dose contained 50 000 IU of vitamin A (retinol palmitate 
and minute amounts of vitamin E [9·5–12·6 IU] in soybean oil) or placebo (minute amounts 
of vitamin E [9·5–12·6 IU] in soybean oil). The vitamin A and placebo capsules were 
identical in taste and appearance. Capsules were individually packed in blister packs of two 
capsules each; one for the dose and the second for the backup dose. Labels for the capsules 
were printed at WHO with country and infant study number in sequential order. Labels were 
first fixed on blister packs containing vitamin A capsules. The capsules were then packed in 
sealed boxes and removed from the packing room before the next treatment group was 
brought in. Investigators had no access to the randomisation list or to any information that 
would allow them to deduce the allocation. Participants’ families, and trial personnel 
(including those distributing capsules and collecting, processing, and analysing data) were 
masked to treatment assignment for the duration of the trial.
Procedures
Nurses or dosing supervisors gave the infants vitamin A or placebo as a single-dose oral 
capsule either at the babies’ home or in labour wards at least 2 h after birth or within the 
next 2 days. Study regimen was stored in cool and dry rooms that had temperatures between 
15°C and 30°C. Temperatures were measured with a thermometer and recorded daily in a 
log book by a pharmacist and study personnel who were not part of the trial. They also 
provided the study coordinators with the capsules that were next in sequence for dosing each 
time the dosing teams needed replenishment. The study coordinators in turn gave each study 
nurse and field interviewer packs to give to the next ten eligible infants before receiving 
another one. The backup dose was given only when there was accidental spillage by the 
person giving the supplement. Enrolled newborn babies were issued child health cards with 
the number written on the blister pack containing the dose. Infant’s birthweight was assessed 
at the facility or home, by study staff at the time of dosing. A wealth index was generated 
from household ownership of durable assets.21
Trained field interviewers visited enrolled infants at home (or in health facilities for cases in 
which the mother and child were not discharged after delivery) 1 day and 3 days after dosing 
to monitor possible adverse events after supplementation. If infants developed any 
unexpected clinical signs or behaviour changes after supplementation, then study staff 
advised mothers or caregivers of newborn babies to take their babies to the nearest health 
facility. Standard care of according to Tanzania Ministry of Health was provided for such 
cases.
Field interviewers did home visits at 1, 3, 6, and 12 months after birth for all enrolled infants 
to find out vital status and to obtain information about any morbidity that resulted in hospital 
admission, feeding in the past 24 h, and immunisation records. Medical reports or mothers’ 
accounts were collected for hospital admission, date of admission, length of hospital stay, 
and reason for admission. To minimise loss to follow-up, caregivers and children who were 
absent at the time of visit were called by phone to reschedule an appointment or the home 
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was revisited twice monthly until the visit was completed. In addition to the field 
interviewers, a network of key informants within HDSS was used to find out vital status and 
report to the study team. All reported deaths of children were investigated and trained field 
staff visited the family at least 6 weeks after the date of death to do a verbal autopsy 
interview.
The three studies17,18 used standard questionnaires with a defined set of core variables. Each 
core variable had a standard definition, acceptable range limits, and an agreed data format. 
Research staff were carefully trained to carry out surveillance, interview families, obtain 
informed consent, administer the study regimen, weigh infants, and collect follow-up 
information. Data were captured electronically using tablet computers and netbooks and 
were uploaded to a main server through a cell network or wireless internet. Detailed range 
and consistency checks were encoded within the electronic data entry platform to ensure 
data quality. Data were further reviewed by the data management team and queries were 
resolved by site supervisors or field coordinators. Clean data were uploaded each month to 
WHO. Site supervisors and field managers called and visited a random sample of mothers 
each week to confirm the accuracy and quality of data collection completed by field 
interviewers. Additionally, field interviewers received supervised visits on a rotating basis.
We tested blood specimens for serum retinol and retinol-binding protein in subsamples of 
infants in vitamin A and placebo treatment groups at age 2 weeks and 3 months to examine 
the effect of supplementation on mean serum retinol, and in a subsample of mothers at 3 
months to ascertain maternal vitamin A status in this population. Written informed consent 
was sought from the mother before a nurse, physician, or lab technician took 0·5–1·0 mL of 
heel-prick blood from the infant and venous blood from consenting mothers. To account for 
spatial and seasonal variation, we randomly sampled across all study areas and seasons.
Blood samples (0·5–1·0 mL for infants and 2·0–5·0 mL for mothers) were collected in 
vacutainers and were sent to the laboratory for serum separation. Serum aliquots were kept 
in cryotubes and stored at −80°C in freezers. Blood samples were analysed at Boston 
Children’s Hospital (MA, USA) for serum retinol, retinol-binding protein, and C-reactive 
protein concentrations. Vitamin A (retinol) concentrations were measured with high-
performance liquid chromatography using a Shimadzu system from R&D Systems 
(Minneapolis, MN, USA). Retinol-binding protein 4 concentrations were measured with an 
ELISA assay from R&D Systems. High-sensitivity C-reactive protein concentrations were 
measured with an immunoturbidimetric assay on the Roche P Modular system (Roche 
Diagnostics, Indianapolis, IN, USA).
Outcomes
Our primary outcome was death between supplementation and 180 days of age (6 months). 
Secondary outcomes were defined as death between supplementation and 28 days of age, 
death between supplementation and 365 days of age, and hospital admission in the first 6 
months of life, which was defined as admission to hospital as an inpatient as reported by the 
mother. In the case of more than one hospital admissions, each infant contributed only their 
first admission to the analysis. Adverse events were defined as any harmful or undesired 
effect reported by the family within 3 days of supplementation. These included death, 
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presence of bulging fontanelle confirmed by research team through physical examination of 
the infant, vomiting, fever, diarrhoea, inability to suck or feed, and convulsions.
Statistical analysis
We planned to enrol 32 000 newborn babies to detect a 15% reduction in mortality from 
enrolment to age 6 months, with 85% power and 5% significance level, assuming infant 
mortality of 60 per 1000 livebirths and a 10% loss to follow-up. This sample size was also 
adequate to detect possible effect sizes of 15% in post-enrolment infant mortality and 20% 
in post-enrolment neonatal mortality (secondary outcome).
Four protocol violations were documented. In two instances, two infants were dosed twice 
with different capsules. For these infants, we analysed data based on the first capsule given. 
In two other instances, the infants received the backup doses of other infants who had 
already been dosed. In these two cases, the infants were analysed according to the dose that 
they received.
We included only children who were not lost to follow up for the primary analyses, which 
were done with SAS version 9.2 using a prespecified plan of analysis.16,22 The intention-to-
treat analysis is included in the appendix. We used both person-time (infant-years of follow-
up) and livebirths as the denominator for the primary and secondary outcomes on mortality. 
We used risk ratios, risk differences, and their corresponding 95% CIs to estimate the effect 
of vitamin A. We also presented χ2 or Fisher’s exact test p values (in cases where there were 
fewer than five observations in a cell). We tested for interactions between intervention and 
sex for both primary and secondary outcomes and presented p values from the likelihood 
ratio test comparing the model with and without the interaction term. We also did analyses 
of all predefined subgroups by sex, birthweight, wealth status, diphtheria, pertussis, and 
tetanus immunisation and maternal vitamin A supplementation.
We compared mean serum retinol and retinol-binding protein in infants given each regimen 
using Student t test and using multiple linear regression adjusting for C-reactive protein 
concentrations. We examined the effect of the supplements on vitamin A status by 
comparing proportions for different cutoffs of vitamin A deficiency severity, defined as mild 
(<1·05 μmol/L), moderate (<0·7 μmol/L), or severe (<0·35 μmol/L).
The study was registered with the Australian New Zealand Clinical Trials Registry 
(ANZCTR), number ACTRN12610000636055.
Role of funding source
Bill & Melinda Gates Foundation funded the study, with funds supplied to the World Health 
Organization. The funder did not have any role in the design of the study, data collection, 
data analysis, data interpretation, or writing of this report. The corresponding author had full 
access to the data in the study and had final responsibility for the decision to submit for 
publication.
Masanja et al. Page 6
Lancet. Author manuscript; available in PMC 2016 April 04.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Results
Between Aug 26, 2010, and March 3, 2013, we identified and assessed 34 133 livebirths for 
eligibility (figure 1). 1290 were not screened because they did not consent, died before 
screening, or could not be contacted. 844 (3%) newborn infants were excluded (figure 1). 
We randomly assigned 31 999 newborn babies to receive either vitamin A (n=15 995) or 
placebo (n=16 004). Most (24 888; 78%) infants received vitamin A or placebo within 24 h 
(table 1). Maternal and infant characteristics were similar in both groups (table 1). Three-
quarters of women received a large dose of vitamin A supplementation within 24 h of birth 
as part of standard of care.
Assessment for infant mortality at age 6 months was based on 15 428 infants allocated to 
vitamin A and 15 464 allocated to placebo (table 2). We recorded 407 infant deaths and a 
mortality rate of 26·38 per 1000 livebirths in the vitamin A group and 372 infant deaths and 
a mortality rate of 24·06 per 1000 livebirths in the placebo group at 6 months. The relative 
risk was 1·10 (95% CI 0·95–1·26; p=0·193), and risk difference was 2·32 (95% CI −1·17 to 
5·82), indicating no effect of supplementation on overall mortality at 6 months. Relative risk 
for mortality at 28 days was 1·04 (95% CI 0·86–1·25; p=0·714). Similarly, mortality at 12 
months (n=29 435) of age was not different between the vitamin A and placebo groups; 
relative risk 1·04 (95% CI 0·93–1·17; p=0·494). The relative risk for admission at 6 months 
was 1·10 (95% CI 0·94–1·28; p=0·233). The effects of vitamin A supplementation on 
primary and secondary endpoints did not differ by sex: interaction with mortality at age 28 
days (p=0·594), 6 months (p=0·760), and 12 months (p=0·111), and hospital admission at 6 
months of age (p=0·422; table 2; figure 2).
In both vitamin A and placebo groups, more than half of infants at 2 weeks and at 3 months 
had moderately low vitamin A concentrations (<0·7 μmol/L). At 2 weeks, mean serum 
retinol concentrations, mean serum retinol-binding protein concentrations, or the proportion 
of infants with serum retinol concentrations lower than 0·7 μmol/L did not differ between 
the two groups. However, at age 3 months, infants in the vitamin A group had a significantly 
higher mean serum retinol concentration than did the placebo group (mean difference 
between the groups 0·043 [95% CI 0·003–0·083]). Similarly, infants in the vitamin A group 
were, on average, less likely to have moderate serum retinol concentrations compared with 
the placebo group at 3 months (relative risk −0·107; 95% CI −0·191 to 0·022). When we 
compared mothers of infants assigned to each group 3 months after birth, there were no 
significant differences in mean serum retinol concentrations, mean serum retinol-binding 
protein concentrations, or proportions of infants with vitamin A deficiency between groups 
(table 3). Adjustment by C-reactive protein did not substantially change serum retinol or 
retinol-binding protein concentration results (data not shown).
Table 4 shows the number of adverse events within 3 days of supplementation by trial 
group. 246 infants died within the first 72 h of supplementation—116 (1%) in the vitamin A 
group and 130 (1%) in the placebo group (relative risk 0·89 [95% CI 0·70–1·15]). We noted 
no significant differences between the vitamin A and placebo groups in the proportion of 
infants who had bulging fontanelle, fever, vomiting, diarrhoea, or inability to feed. Bulging 
fontanelle was observed in 41 children: 21 (<1%) in the vitamin A group and 20 (<1%) in 
Masanja et al. Page 7
Lancet. Author manuscript; available in PMC 2016 April 04.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
the placebo group. Five (<1%) infants in the placebo group had convulsions compared with 
none in the vitamin A group.
In the appendix we include analyses for the effect of vitamin A supplementation on adverse 
events using all enrolled newborn babies instead of limiting analyses to those who were 
assessed in the first 3 days of life (appendix). Similarly, we examined the effect of 
supplementation on mortality at 28 days, 6 months, and 12 months and on hospital 
admission at age 6 months for all enrolled infants (appendix) and person-time analyses 
(appendix). In all cases, the results were not substantially different from the analyses 
presented above. Finally, we presented the effect of neonatal vitamin A on mortality at 6 
months within strata of birthweight, wealth, maternal vitamin A supplementation, and 
receipt of diphtheria, pertussis, and tetanus 1 vaccine. There was no evidence of 
modification of the effect of vitamin A by any of these variables. We will further examine 
subgroup analyses by pooling data across the three companion trials, in which statistical 
power will be greater.
Discussion
Provision of one dose of vitamin A at birth was thought to be a low-cost intervention that 
could have significant protective effects on development of the immune system and early 
infant mortality.23 In this trial we did not show a beneficial effect on survival at age 6 
months in infants given vitamin A supplementation within the first 3 days after birth, 
although the findings do not exclude the possibility of a slight increased risk of death.
Our results are consistent with a companion trial in Ghana (n=22 955),18 which reported a 
non-significant 12% increased risk in mortality by 6 months after vitamin A 
supplementation (risk ratio 1·12 [95% CI 0·95–1·33]). The results of these two new large 
trials are consistent with findings from a trial in Zimbabwe,15 in which the relative risk for 
neonatal supplementation was 1·12 (95% CI 0·80–1·57). Although the confidence intervals 
for the findings from our and these two trials were not significant at the conventional 5% 
level, the findings do not exclude the possibility of harm from neonatal vitamin A 
supplementation. By contrast, findings from the second companion trial in India (n=44 
984)17 indicated that neonatal supplementation resulted in a non-significant reduction in 
mortality (relative risk 0·90 [95% CI 0·81–1·00]), consistent with findings from two 
previously trials in India24 and Bangladesh.12 The differences in efficacy between these 
trials are probably attributable to differences in background characteristics of the study 
population. A key element might be the prevalence of moderate or severe vitamin A 
deficiency, which is higher in studies that report beneficial effects.
A notable finding from our trial is that neonatal vitamin A supplementation resulted in 
improved vitamin A status at 3 months; however, there was no effect on vitamin A status at 
2 weeks. At both timepoints, more than 50% of infants in vitamin A and placebo groups still 
had vitamin A concentrations below the cutoff typically suggestive of moderate deficiency 
(<0·7 μmol/L). The clinical importance of these findings is not clear since not many data 
exist about absolute serum vitamin A concentrations in infants and their relation to vitamin 
A status. Supplementation had little effect on serum retinol concentrations in infants at both 
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timepoints in Ghana.18 It is plausible that the large dose of vitamin A supplementation is not 
optimally absorbed, possibly leading to poor clinical effect.
We did not find the effects of vitamin A to be different in boys compared with girls, 
contrary to reports from Guinea-Bissau by Benn and colleagues,14,25,26 who reported excess 
mortality among girls supplemented with vitamin A. Our results are consistent with the two 
companion trials17,18 and a meta-analysis.27 However, our overall findings, and the results 
from Ghana and Zimbabwe, do not exclude the possibility of potential harm from neonatal 
supplementation. Consistent with the effect of supplementation on mortality by 6 months, 
the relative risk of hospital admission was 1·10 (95% CI 0·94–1·28) in Tanzania, and 1·11 
(95% CI 1·00–1·22) in Ghana. Pooling data across the three companion trials will provide a 
unique opportunity to examine potential modifiers that identify subgroups of children who 
might be positively or adversely affected by neonatal supplementation, including 
birthweight, gestational age at birth, maternal vitamin A status, and vaccine use in early 
infancy, among others. In our study, vitamin A supplementation in newborn infants did not 
result in any immediate adverse events. Rates of adverse events at 3 days after 
supplementation were similar between the vitamin A and placebo groups. Similar findings 
were reported in a meta-analysis23 and the accompanying trial from Ghana.18 By contrast, 
the companion trial in India17 showed a small excess risk of transient bulging fontanelle in 
the vitamin A supplementation group compared with the placebo group.
Panel: Research in context
Systematic review
We searched all English language articles published in PubMed and Cochrane Database 
of Systematic Reviews between Jan 1, 1980, and Dec 31, 2013, using the search terms: 
“newborn”, “neonatal”, “vitamin A”, “supplementation”, “child mortality”, “individual 
randomised”, and “cluster randomised trials”. We manually examined the results. We 
reviewed published clinical trials with mortality at 6 months of age as primary endpoint. 
We found 39 published randomised controlled trials and meta-analyses, which showed 
evidence for benefits of vitamin A supplementation in children aged 6–59 months. 
Evidence to support whether supplementation provided similar benefits in children 
younger than 6 months had conflicting results, ranging from no benefit, potential benefit, 
or possible harm in subsets of children.
Interpretation
Supplementation of newborn babies with vitamin A on the day of birth or within the next 
2 days of life did not provide a survival benefit in Tanzanian infants at 6 months of age. 
Vitamin A supplementation was well tolerated, and no differential effects were found 
between boys and girls. These findings do not support a global policy for newborn 
vitamin A supplementation. For global policy formulation, assessment should be done of 
potential modifiers from pooled data and meta-analyses from all other trials to carefully 
understand safety and efficacy of newborn vitamin A supplementation in subsets of 
children among whom the intervention might be beneficial.
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Although our trial is the largest randomised, double-blind, placebo-controlled study on this 
subject in sub-Saharan Africa so far (panel) and it was designed with statistical power to 
ascertain a 15% effect size, mortality to age 6 months was lower than we had assumed. The 
most likely explanation for this low mortality is the recent increased spending on health, and 
improved coverage of childhood interventions (eg, insecticide-treated bednets for malaria 
prevention, exclusive breastfeeding, high equitable level of child immunisation) in 
Tanzania.28 Our study had high ascertainment of the outcomes of interest, as shown by the 
low loss to follow-up rates both at 6 months (3·5%) and at 12 months of age (4·8%), despite 
many challenges throughout the implementation of the study.
Neonatal vitamin A supplementation was not associated with any immediate adverse events. 
Further more, findings from this trial do not support survival benefit in infants at 6 months 
of age. Although the trials from Tanzania and Ghana indicate no overall benefit and some 
plausible risk for supplementation, for formulation of global policy, analyses of pooled data 
from the three large companion trials and meta-analyses of all other trials will be important 
to carefully understand the safety and efficacy of vitamin A supplementation in subsets of 
children in whom the intervention might be beneficial.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Trial profile
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Figure 2. 
Kaplan-Meier survival curve up to 12 months
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Table 1
Baseline characteristics
Vitamin A group (n=15 995) Placebo group (n=16 004)
Infant characteristics
Boys* 8443 (52·8%) 8340 (52·1%)
Age at dosing
 <12 h 7552 (47·2%) 7663 (47·9%)
 12–23 h 4847 (30·3%) 4826 (30·2%)
 24–47 h 2876 (18%) 2791 (17·4%)
 ≥48 h 282 (1·8%) 299 (1·9%)
 Mean (h) 15·5 (12) 15·4 (12)
Birthweight
 Mean (kg) 3·02 (1) 3·02 (1)
 Less than 2·5 kg 1908 (11·9%) 1974 (12·3%)
Twin or triplet 539 (3·4%) 569 (3·6%)
Breastfed before supplementation* 15 750 (98·5%) 15 740 (98·4%)
Mean age at breastfeeding initiation (h) 1·08 (4) 0·99 (4)
Vaccination with first DPT vaccine*
 Yes 14 281 (89·3%) 14 345 (89·6%)
 No 771 (4·8%) 773 (4·8%)
Mean age at vaccination (days) 43·7 (20) 43·8 (19)
Number of living children*
 One 3337 (20·9%) 3284 (20·5%)
 Two 4469 (27·9%) 4629 (28·9%)
 Three or more 7749 (48·4%) 7638 (47·7%)
Number of children who have died*
 First birth 2912 (18·2%) 2832 (17·7%)
 None 9820 (61·4%) 9834 (61·4%)
 One 1009 (6·3%) 1075 (6·7%)
 Two or more 814 (5·1%) 844 (5·3%)
Born in health facility 13 921 (87%) 13 902 (86·9%)
Maternal characteristics
Maternal age*
 <20 years 2274 (14·2%) 2209 (13·8%)
 20–24 years 4650 (29·1%) 4652 (29·1%)
 25–29 years 4377 (27·4%) 4405 (27·5%)
 ≥30 years 4235 (26·5%) 4300 (26·9%)
Highest educational level*
 None 1335 (8·3%) 1310 (8·2%)
 Primary 11 988 (74·9%) 12 066 (75·4%)
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Vitamin A group (n=15 995) Placebo group (n=16 004)
 Secondary 1026 (6·4%) 1018 (6·4%)
 More than secondary 465 (2·9%) 454 (2·8%)
Wealth quintile of household*
 First (lowest) 2894 (18·1%) 2943 (18%)
 Second 2978 (18·6%) 2879 (18%)
 Third 2863 (17·9%) 2863 (18%)
 Fourth 2949 (18·4%) 2996 (19%)
 Fifth (highest) 3290 (20·6%) 3308 (21%)
Received mega-dose of vitamin A*
 Yes 12 130 (75·8%) 12 101 (75·6%)
 No 3655 (22·9%) 3677 (23·0%)
Data are n (%) or mean (SD). DPT=diphtheria, pertussis, and tetanus.
*
The numbers do not add up to 100% because of missing data.
Lancet. Author manuscript; available in PMC 2016 April 04.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Masanja et al. Page 17
Ta
bl
e 
2
Ef
fe
ct
 o
f v
ita
m
in
 A
 o
n 
en
dp
oi
nt
s
V
ita
m
in
 A
 g
ro
up
Pl
ac
eb
o 
gr
ou
p
R
isk
 p
er
 1
00
0 
in
 
v
ita
m
in
 A
 g
ro
up
R
isk
 p
er
 1
00
0 
in
 
pl
ac
eb
o 
gr
ou
p
R
isk
 d
iff
er
en
ce
 p
er
 1
00
0 
(95
%
 C
I)
R
isk
 r
at
io
 (9
5%
 C
I)
p 
va
lu
e
Ev
en
ts
N
ew
bo
rn
s
Ev
en
ts
N
ew
bo
rn
s
M
or
ta
lit
y 
at
 6
 m
on
th
s (
n=
30
 89
2)
O
ve
ra
ll
40
7
15
 4
28
37
2
15
 4
64
26
·3
8
24
·0
6
2·
32
 (−
1·1
7 t
o 5
·82
)
1·
10
 (0
·95
 to
 1·
26
)
0·
19
3
B
oy
s
23
3
81
35
21
5
80
70
28
·6
4
26
·6
4
2·
00
 (−
3·0
5 t
o 7
·05
)
1·
08
 (0
·90
 to
 1·
29
)
0·
43
8
G
irl
s
17
4
72
91
15
7
73
92
23
·8
7
21
·2
4
2·
63
 (−
2·1
8 t
o 7
·43
)
1·
12
 (0
·91
 to
 1·
39
)
0·
28
4
In
te
ra
ct
io
n 
w
ith
 se
x
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
0·
76
0
N
eo
na
ta
l m
or
ta
lit
y 
(n
=3
1 3
87
)
O
ve
ra
ll
21
3
15
 6
77
20
6
15
 7
10
13
·5
9
13
·1
1
0·
47
 (−
2·0
7 t
o 3
·01
)
1·
04
 (0
·86
 to
 1·
25
)
0·
71
4
B
oy
s
12
4
82
73
12
4
81
98
14
·9
9
15
·1
3
−
0·
14
 (−
3·8
6 t
o 3
·58
)
0·
99
 (0
·77
 to
 1·
27
)
0·
94
2
G
irl
s
89
74
02
82
75
10
12
·0
2
10
·9
2
1·
11
 (−
2·3
1 t
o 4
·52
)
1·
10
 (0
·82
 to
 1·
48
)
0·
52
6
In
te
ra
ct
io
n 
w
ith
 se
x
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
0·
59
4
M
or
ta
lit
y 
at
 1
2 
m
on
th
s (
n=
29
 43
5)
O
ve
ra
ll
56
6
14
 6
86
54
6
14
 7
49
39
37
1·
52
 (−
2·8
4 t
o 5
·88
)
1·
04
 (0
·93
 to
 1·
17
)
0·
49
4
B
oy
s
31
2
77
45
32
4
77
13
40
42
−
1·
72
 (−
7·9
9 t
o 4
·54
)
0·
96
 (0
·82
 to
 1·
12
)
0·
59
0
G
irl
s
25
4
69
39
22
2
70
34
37
32
5·
04
 (−
0·9
7 t
o 1
1·0
6)
1·
16
 (0
·97
 to
 1·
38
)
0·
10
0
In
te
ra
ct
io
n 
w
ith
 se
x
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
0·
11
1
H
os
pi
ta
l a
dm
iss
io
n 
up
 to
 6
 m
on
th
s (
n=
30
 89
5)
O
ve
ra
ll
33
2
15
 4
29
30
3
15
 4
66
21
·5
2
19
·5
9
1·
93
 (−
1·2
4 t
o 5
·09
)
1·
10
 (0
·94
 to
 1·
28
)
0·
23
3
B
oy
s
19
4
81
35
16
6
80
72
23
·8
5
20
·5
6
3·
28
 (−
1·2
5 t
o 7
·82
)
1·
16
 (0
·94
 to
 1·
42
)
0·
15
6
G
irl
s
13
8
72
92
13
7
73
92
18
·9
2
18
·5
3
0·
39
 (−
3·9
9 t
o 4
·78
)
1·
02
 (0
·81
 to
 1·
29
)
0·
86
1
In
te
ra
ct
io
n 
w
ith
 se
x
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
0·
42
2
A
ll 
ev
en
t r
at
es
 g
iv
en
 o
ve
r p
ar
tic
ip
an
ts 
no
t l
os
t t
o 
fo
llo
w
-u
p 
be
fo
re
 e
nd
 o
f r
isk
 p
er
io
d.
Lancet. Author manuscript; available in PMC 2016 April 04.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Masanja et al. Page 18
Table 3
Serum retinol and retinol-binding protein concentrations in infants and mothers after supplementation
Vitamin A Placebo Mean difference or risk difference (95% CI) p value
Infants at age 2 weeks
Number tested 277 284 ·· ··
Infants with serum retinol results 255 (92%) 265 (93%) ·· ··
Mean serum retinol (μmol/L) 0·69 (0·20) 0·69 (0·22) 0 (0–40·03) 0·930
Serum retinol <1·05 μmol/L 240 (94%) 249 (94%) 0·16 (−3·91 to 4·23) 0·940
Serum retinol <0·70 μmol/L 144 (57%) 142 (54%) 2·89 (−5·66 to 11·43) 0·508
Serum retinol <0·35 μmol/L 4 (2%) 8 (3%) −1·45 (−4·01 to 1·11) 0·383*
Infants with serum retinol-binding protein results 277 (100%) 284 (100%) ·· ··
Mean serum retinol-binding protein in μmol/L 0·79 (0·20) 0·80 (0·23) −0·01 (−0·05 to 0·02) 0·429
Retinol-binding protein <0·70 μmol/L 98 (35%) 91 (32%) 3·34(−4·48 to 11·16) 0·403
Retinol-binding protein <0·35 μmol/L 1 (<1%) 3 (1%) −0·70(−2·08 to 0·69) 0·624*
Infants at age 3 months
Number tested 280 266 ·· ··
Infants with serum retinol results 271 (97%) 255 (96%) ·· ··
Mean serum retinol (μmol/L) 0·72 (0·23) 0·68 (0·24) 0·04 (0–0·08) 0·035
Serum retinol <1·05 μmol/L 250 (92%) 238 (93%) −1·08 (−5·50 to 3·33) 0·632
Serum retinol <0·70 μmol/L 138 (51%) 157 (62%) −10·65 (−19·08 to 2·22) 0·014
Serum retinol <0·35 μmol/L 8 (3%) 7 (3%) 0·21 (−2·64 to 3·05) 0·887
Infants with serum retinol-binding protein results 280 (100%) 266 (100%) ·· ··
Mean serum retinol-binding protein (μmol/L) 0·77 (0·20) 0·74 (0·24) 0·03 (0–0·07) 0·075
Retinol-binding protein <0·70 μmol/L 115 (41%) 133 (50%) −8·93 (−17·25 to 0·6) 0·036
Retinol-binding protein <0·35 μmol/L 2 (1%) 2 (1%) −0·04 (−1·47 to 1·39) 1·000*
Mothers
Number tested 262 253 ·· ··
Mothers with serum retinol results 262 (100%) 253 (100%) ·· ··
Mean serum retinol (μmol/L) 1·25 (0·42) 1·22 (0·39) 0·03 (−0·04 to 0·10) 0·418
Serum retinol <1·05 μmol/L 82 (31%) 90 (36%) −4·28 (−12·42 to 3·87) 0·304
Serum retinol <0·70 μmol/L 13 (5%) 21 (8%) −3·34 (−7·64 to 0·96) 0·127
Serum retinol <0·35 μmol/L 0 2 (1%) −0·79 (−1·88 to 0·3) 0·241*
Mothers with serum retinol-binding protein results 262 (100%) 253 (100%) ·· ··
Mean serum retinol-binding protein (μmol/L) 1·23 (0·39) 1·21 (0·34) 0·02 (−0·05 to 0·08) 0·566
Retinol-binding protein <0·70 μmol/L 16 (6%) 12 (5%) 1·36 (−2·54 to 5·27) 0·495
Retinol-binding protein <0·35 μmol/L 0 0 ·· ··
*Calculated with Fisher’s exact test p value.
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Table 4
Adverse events within 3 days
Vitamin A group Placebo group Risk ratio (95% CI) p value
All infants (n=31 627)
Death within 3 days of supplementation 116 (0·73%) 130 (0·82%) 0·89 (0·7–1·15) 0·378
Infants with data for adverse events within 3 days (n=29 041)
Examined bulging fontanelle 21 (0·14%) 20 (0·14%) 1·05 (0·57–1·94) 0·877
Fever 174 (1·2%) 179 (1·23%) 0·97 (0·79–1·20) 0·786
Vomiting 26 (0·18%) 17 (0·12%) 1·53 (0·83–2·82) 0·170
Diarrhoea 3 (0·02%) 5 (0·03%) 0·60 (0·14–2·51) 0·479
Inability to suck or feed 30 (0·21%) 29 (0·2%) 1·03 (0·62–1·72) 0·897
Convulsion 0 (0%) 5 (0·03%) ·· 0·031*
*
Fisher’s exact test p value.
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